Compare HSBC Holdings plc (HSBC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Recursion Pharmaceuticals Inc — how do they compare? HSBC Holdings plc trades at $101.13 (market cap $335.21B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: HSBC Holdings plc is far larger — about 219.1× Recursion Pharmaceuticals Inc's market cap, and HSBC Holdings plc pays a 3.79% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HSBC | RXRX | |
|---|---|---|
Market Cap | $335.21B | $1.53B |
Sector | Technology | Health |
52-Week High | $100.61 | $6.79 |
52-Week Low | $61.30 | $2.84 |
Dividend Yield | 3.79% | — |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows bullish technical momentum with strong moving average support and recent earnings beats in Q3 and Q4 2025. Revenue grew to $71.02B in 2025 with a healthy 30.81% net margin, though Q1 2026 missed expectations. Analyst sentiment is mixed with 38% buy ratings while the company executes strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a balanced opportunity with solid profitability and strategic repositioning, but faces execution risks in its global restructuring. The current valuation at 16.37 P/E appears reasonable for a global bank, though regulatory challenges and market volatility require monitoring. Near-term catalysts include the upcoming Q2 earnings and continued progress on business simplification initiatives.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
